[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Contribution
September 2006

Clinical Heterogeneity of the LRRK2 G2019S Mutation

Author Affiliations

Author Affiliations: Department of Neurology, University of Miami School of Medicine, Miami, Fla (Drs Papapetropoulos, Singer, and Mash); and Department of Neuroscience, Mayo Clinic Jacksonville College of Medicine, Jacksonville, Fla (Drs Ross, Toft, Johnson, and Farrer).

Arch Neurol. 2006;63(9):1242-1246. doi:10.1001/archneur.63.9.1242

Background  Several pathogenic mutations have been reported in the leucine-rich repeat kinase 2 gene (LRRK2) that cause parkinsonism. The “common” LRRK2 G2019S kinase domain substitution has been reported to account for approximately 5% of familial and 1% of sporadic Parkinson disease.

Objective  To observe the clinical heterogeneity presented by LRRK2 kinase mutation carriers.

Design, Setting, and Participants  We screened 130 patients with pathologically confirmed Parkinson disease and 85 controls for 3 LRRK2 kinase domain pathogenic substitutions: I2012T, G2019S, and I2020T.

Main Outcome Measures  Detailed clinical phenotypes for individuals who screened positive for LRRK2 mutations.

Results  Five LRRK2 G2019S carriers were identified, of whom 4 had Parkinson disease (clinically and pathologically confirmed), and the fifth was a control subject who died at age 68 years after an acute myocardial infarction with no evidence of neurodegenerative abnormalities. There was no evidence of the I2012T or I2020T mutation in these participants.

Conclusions  The underlying disease mechanisms of LRRK2 G2019S–associated parkinsonism are similar to those of typical Parkinson disease. The identification of a control subject raises important questions concerning genetic diagnosis and counseling.